Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Here's Why Ovid Therapeutics Stock Popped Higher Today
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts
Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
Ovid Therapeutics Inc. - Special Call
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results